

APAC Melanoma Cancer Diagnostics Market - Industry Trends and Forecast to 2030

Market Report | 2022-11-01 | 244 pages | Data Bridge Market Research

AVAILABLE LICENSES:

- Single User License \$3500.00
- Corporate Users License \$4200.00

Report description:

The Asia-Pacific melanoma cancer diagnostics market is projected to register a substantial CAGR of 8.3% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.

Market Segmentation:

Asia-Pacific Melanoma Cancer Diagnostics Market, By Product Type (Instruments, Consumables and Accessories, and Others), Test Type (Biomarkers Test, Imaging Test, Biopsy, Fluorescent In Situ Hybridization (FISH) Tests, Comparative Genomic Hybridization (CGH) tests, Immunohistochemical (IHC) tests, and Others), End User (Hospitals, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes and Others), Distribution channel (Direct Tender and Retail Sales), Country (Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific) Industry Trends and Forecast to 2030

Some of the major factors contributing to the growth of the Asia-Pacific melanoma cancer diagnostics market are:

- Increase in the prevalence of melanoma cancer
- Rise in the adoption of new technologies and easy accessibility for laboratory professionals

Market Players:

Some of the major players operating in the Asia-Pacific melanoma cancer diagnostics market are:

- Thermo Fisher Scientific Inc.
- Quest Diagnostics Incorporated
- Agilent Technologies, Inc.
- QIAGEN
- F. Hoffman-La Roche Ltd
- Abbott
- Myriad Genetics, Inc.
- Illumina, Inc.
- bioMerieux SA

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- NanoString
- Skin Analytics

Table of Contents:

TABLE OF CONTENTS	
1 INTRODUCTION	48
1.1 OBJECTIVES OF THE STUDY	48
1.2 MARKET DEFINITION	48
1.3 OVERVIEW OF THE ASIA PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET	48
1.4 LIMITATIONS	50
1.5 MARKETS COVERED	50
2 MARKET SEGMENTATION	53
2.1 MARKETS COVERED	53
2.2 GEOGRAPHICAL SCOPE	54
2.3 YEARS CONSIDERED FOR THE STUDY	55
2.4 CURRENCY AND PRICING	55
2.5 DBMR TRIPOD DATA VALIDATION MODEL	56
2.6 MULTIVARIATE MODELLING	60
2.7 PRODUCT TYPE LIFELINE CURVE	60
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS	61
2.9 DBMR MARKET POSITION GRID	62
2.10 MARKET END USER COVERAGE GRID	63
2.11 VENDOR SHARE ANALYSIS	64
2.12 SECONDARY SOURCES	65
2.13 ASSUMPTIONS	65
3 EXECUTIVE SUMMARY	66
4 PREMIUM INSIGHTS	68
4.1 PESTEL'S MODEL	69
4.2 PORTER'S FIVE FORCES MODEL	70
5 EPIDEMIOLOGY	71
6 INDUSTRY INSIGHTS	72
6.1 DEMOGRAPHIC TRENDS	72
6.2 KEY PRICING STRATEGIES	73
6.2.1 PRODUCT INNOVATION	73
6.2.2 CONSUMER AWARENESS	73
6.2.3 A VAST NETWORK OF DISTRIBUTION	73
6.2.4 PARTNERSHIP WITH POPULAR BRANDS BY MAJOR PLAYERS	74
6.2.5 OTHERS	74
6.3 KEY PATIENT ENROLLMENT STRATEGIES	74
6.3.1 IDENTIFICATION OF CUSTOMERS NEED FOR INNOVATIVE DIAGNOSTIC PRODUCTS	74
6.3.2 INCREASING SPECIFIC TACTICS FOR EVERY STEP	74
6.3.3 EDUCATE AND COMMUNICATE	75
6.3.4 IMPROVING DIAGNOSIS SEEKING RATE	75
6.4 INTERVIEWS WITH MANUFACTURING COMPANIES	75
7 MARKET OVERVIEW	77

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

7.1 DRIVERS	79
7.1.1 GROWING PREVALENCE OF MELANOMA CANCER	79
7.1.2 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS	80
7.1.3 NOVEL TECHNOLOGIES IN MELANOMA CANCER DIAGNOSTICS	81
7.1.4 INCREASING AWARENESS REGARDING MELANOMA CANCER	82
7.2 RESTRAINTS	82
7.2.1 LACK OF SKILLED AND CERTIFIED PROFESSIONALS	82
7.2.2 HIGH COST OF DIAGNOSTICS PROCEDURE FOR MELANOMA CANCERS	83
7.3 OPPORTUNITIES	83
7.3.1 INCREASING HEALTHCARE EXPENDITURE FOR MELANOMA CANCER TREATMENT	83
7.3.2 GOVERNMENT INITIATIVES TOWARD MELANOMA CANCER DIAGNOSTICS	84
7.3.3 INCREASED DEMAND FOR NON-INVASIVE TESTING METHODS	85
7.3.4 GROWING DEMAND FOR BETTER QUALITY HEALTHCARE	85
7.4 CHALLENGES	86
7.4.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF MELANOMA CANCER DIAGNOSTIC PRODUCTS	86
7.4.2 RADIATION RISKS FROM IMAGING TESTS	86
8 ASIA PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE	87
8.1 OVERVIEW	88
8.2 INSTRUMENTS	91
8.2.1 IMAGING INSTRUMENTS	92
8.2.1.1 ULTRASOUND SYSTEMS	92
8.2.1.2 MRI SYSTEMS	92
8.2.1.3 CT SYSTEMS	92
8.2.1.4 OTHERS	93
8.2.2 BIOPSY INSTRUMENTS	93
8.2.3 PATHOLOGY-BASED INSTRUMENTS	93
8.2.3.1 PCR INSTRUMENTS	93
8.2.3.2 CELL PROCESSORS	93
8.2.3.3 SLIDE STAINING SYSTEMS	93
8.2.3.4 TISSUE PROCESSING SYSTEMS	94
8.2.3.5 OTHER PATHOLOGY-BASED INSTRUMENTS	94
8.3 CONSUMABLES & ACCESSORIES	94
8.3.1 KITS	95
8.3.1.1 PCR KITS	95
8.3.1.2 NUCLEIC ACID ISOLATION KITS	95
8.3.1.3 DNA POLYMERASE KITS	95
8.3.1.4 OTHERS	96
8.3.2 PROBES	96
8.3.2.1 Q FISH	96
8.3.2.2 FLOW FISH	96
8.3.2.3 OTHERS	96
8.3.3 REAGENTS	96
8.3.3.1 ASSAYS	97
8.3.3.2 BUFFERS	97
8.3.3.3 PRIMERS	97
8.3.3.4 OTHERS	97

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

8.3.4 OTHER CONSUMABLES	97
8.4 OTHERS	97
9 ASIA PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE	99
9.1 OVERVIEW	100
9.2 IMAGING TEST	103
9.2.1 ULTRASOUND	104
9.2.2 MRI	104
9.2.3 CHEST X-RAY	104
9.2.4 LYMPHOSCINTIGRAPHY	105
9.2.5 COMPUTED TOMOGRAPHY (CT) SCAN	105
9.2.6 POSITRON EMISSION TOMOGRAPHY (PET) SCAN	105
9.2.7 OTHERS	105
9.3 BIOPSY	105
9.3.1 OPTICAL BIOPSY	106
9.3.2 EXCISIONAL BIOPSY	106
9.3.3 INCISIONAL BIOPSY	106
9.3.4 SHAVE BIOPSY	107
9.3.5 PUNCH BIOPSY	107
9.3.6 OTHERS	107
9.4 IMMUNOHISTOCHEMICAL (IHC) TESTS	107
9.4.1 S100 PROTEIN FAMILY BIOPSY	108
9.4.2 MELAN-A	108
9.4.3 PMEL/PMEL17/SILV/GP100	108
9.4.4 TYROSINASE	108
9.4.5 MITF	108
9.4.6 SM5-1	108
9.4.7 CSPG4/HMW-MAA	108
9.5 BIOMARKER TEST	109
9.5.1 BRAF MUTATION TEST	110
9.5.2 NRAS MUTATION TEST	110
9.5.3 CKIT TEST	110
9.5.4 OTHERS	110
9.6 FLUORESCENT IN SITU HYBRIDIZATION (FISH) TESTS	110
9.7 COMPARATIVE GENOMIC HYBRIDIZATION (CGH) TESTS	111
9.8 OTHERS	112
10 ASIA PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET, BY END USER	113
10.1 OVERVIEW	114
10.2 HOSPITALS	117
10.3 ASSOCIATED LABS	118
10.4 DIAGNOSTIC IMAGING CENTERS	118
10.5 INDEPENDENT DIAGNOSTIC LABORATORIES	119
10.6 CANCER RESEARCH INSTITUTES	120
10.7 OTHERS	121
11 ASIA PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL	122
11.1 OVERVIEW	123
11.2 DIRECT TENDER	126
11.3 RETAIL SALES	126

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

12 ASIA PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION	128
12.1 ASIA-PACIFIC	129
12.1.1 AUSTRALIA	139
12.1.2 CHINA	144
12.1.3 INDIA	149
12.1.4 NEW ZEALAND	154
12.1.5 INDONESIA	159
12.1.6 JAPAN	164
12.1.7 THAILAND	169
12.1.8 PHILIPPINES	174
12.1.9 VIETNAM	179
12.1.10 MALAYSIA	184
12.1.11 SOUTH KOREA	189
12.1.12 SINGAPORE	194
12.1.13 TAIWAN	199
12.1.14 REST OF ASIA PACIFIC	204
13 ASIA PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE	205
13.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC	205
14 SWOT ANALYSIS	206
15 COMPANY PROFILE	207
15.1 ABBOTT	207
15.1.1 COMPANY SNAPSHOT	207
15.1.2 REVENUE ANALYSIS	207
15.1.3 COMPANY SHARE ANALYSIS	208
15.1.4 PRODUCT PORTFOLIO	208
15.1.5 RECENT DEVELOPMENTS	208
15.2 ILLUMINA, INC.	209
15.2.1 COMPANY SNAPSHOT	209
15.2.2 REVENUE ANALYSIS	209
15.2.3 COMPANY SHARE ANALYSIS	210
15.2.4 PRODUCT PORTFOLIO	210
15.2.5 RECENT DEVELOPMENT	210
15.3 BIOMERIEUX SA	211
15.3.1 COMPANY SNAPSHOT	211
15.3.2 REVENUE ANALYSIS	211
15.3.3 COMPANY SHARE ANALYSIS	212
15.3.4 PRODUCT PORTFOLIO	212
15.3.5 RECENT DEVELOPMENTS	212
15.4 THERMO FISHER SCIENTIFIC INC.	213
15.4.1 COMPANY SNAPSHOT	213
15.4.2 REVENUE ANALYSIS	213
15.4.3 COMPANY SHARE ANALYSIS	214
15.4.4 PRODUCT PORTFOLIO	214
15.4.5 RECENT DEVELOPMENT	214
15.5 F. HOFFMANN-LA ROCHE LTD.	215
15.5.1 COMPANY SNAPSHOT	215
15.5.2 REVENUE ANALYSIS	215

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

15.5.3 COMPANY SHARE ANALYSIS	216
15.5.4 PRODUCT PORTFOLIO	216
15.5.5 RECENT DEVELOPMENT	216
15.6 AGILENT TECHNOLOGIES, INC.	217
15.6.1 COMPANY PROFILE	217
15.6.2 REVENUE ANALYSIS	217
15.6.3 PRODUCT PORTFOLIO	218
15.6.4 RECENT DEVELOPMENT	218
15.7 AMLO BIOSCIENCES LIMITED	219
15.7.1 COMPANY PROFILE	219
15.7.2 PRODUCT PORTFOLIO	219
15.7.3 RECENT DEVELOPMENT	219
15.8 CASTLE BIOSCIENCES INC	220
15.8.1 COMPANY SNAPSHOT	220
15.8.2 REVENUE ANALYSIS	220
15.8.3 PRODUCT PORTFOLIO	221
15.8.4 RECENT DEVELOPMENT	221
15.9 DAMAE MEDICAL	222
15.9.1 COMPANY PROFILE	222
15.9.2 PRODUCT PORTFOLIO	222
15.9.3 RECENT DEVELOPMENT	222
15.10 DERMLITE.	223
15.10.1 COMPANY PROFILE	223
15.10.2 PRODUCT PORTFOLIO	223
15.10.3 RECENT DEVELOPMENTS	223
15.11 DERMASENSOR	224
15.11.1 COMPANY PROFILE	224
15.11.2 PRODUCT PORTFOLIO	224
15.11.3 RECENT DEVELOPMENT	224
15.12 DERMTECH	225
15.12.1 COMPANY SNAPSHOT	225
15.12.2 REVENUE ANALYSIS	225
15.12.3 PRODUCT PORTFOLIO	226
15.12.4 RECENT DEVELOPMENT	226
15.13 INIVATA LTD.	227
15.13.1 COMPANY PROFILE	227
15.13.2 PRODUCT PORTFOLIO	227
15.13.3 RECENT DEVELOPMENT	227
15.14 MICHAEL DIAGNOSTICS LTD	228
15.14.1 COMPANY SNAPSHOT	228
15.14.2 PRODUCT PORTFOLIO	228
15.14.3 RECENT DEVELOPMENT	228
15.15 MYRIAD GENETICS, INC.	229
15.15.1 COMPANY SNAPSHOT	229
15.15.2 REVENUE ANALYSIS	229
15.15.3 PRODUCT PORTFOLIO	230
15.15.4 RECENT DEVELOPMENT	230

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

15.16 NANOSTRING	231
15.16.1 COMPANY SNAPSHOT	231
15.16.2 REVENUE ANALYSIS	231
15.16.3 PRODUCT PORTFOLIO	232
15.16.4 RECENT DEVELOPMENT	232
15.17 NERACARE GMBH	233
15.17.1 COMPANY PROFILE	233
15.17.2 PRODUCT PORTFOLIO	233
15.17.3 RECENT DEVELOPMENT	233
15.18 SKIN ANALYTICS	234
15.18.1 COMPANY PROFILE	234
15.18.2 PRODUCT PORTFOLIO	234
15.18.3 RECENT DEVELOPMENT	234
15.19 SKYLINEDX	235
15.19.1 COMPANY PROFILE	235
15.19.2 PRODUCT PORTFOLIO	235
15.19.3 RECENT DEVELOPMENTS	235
15.20 VERISKIN INC.	236
15.20.1 COMPANY PROFILE	236
15.20.2 PRODUCT PORTFOLIO	236
15.20.3 RECENT DEVELOPMENTS	236

APAC Melanoma Cancer Diagnostics Market - Industry Trends and Forecast to 2030

Market Report | 2022-11-01 | 244 pages | Data Bridge Market Research

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$3500.00
	Corporate Users License	\$4200.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-09"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com